Harrow Health, Inc.

Harrow announced a long-term five-year strategy at the Cantor Healthcare Conference and aims to position itself as a full-service provider for ophthalmology practices. Management reaffirmed the goal of reaching quarterly revenue of $250 million in calendar year 2027, but described the figure as a target rather than a formal forecast. Growth drivers are expected to be VEVYE, IHEEZO, the G-MELT program and the acquisition of TYRVAYA; the company also flagged risks around pricing, reimbursement and competition. Harrow expects a stronger second half of 2024, is expanding its field force and retina team, and plans further M&A to strengthen its core segments of eye surgery, retina and the ocular surface. » Więcej na de.investing.com

Harrow Health reported Q2 2026 revenue of $70.7m (+11% yoy) and an adjusted loss of $0.46 per share versus an expected loss of $0.11. Management affirmed its full-year guidance of $350–365m revenue and $80–100m adjusted EBITDA, cited VEVYE and IHEEZO as the main growth drivers, and expected margin improvement in H2. High SG&A expenses led to a negative adjusted EBITDA of -$1.2m, and the stock traded lower pre-market. » Więcej na de.investing.com

At the annual meeting of the American Society of Retina Specialists, Harrow presented data on IHEEZO (chloroprocaine gel) and the biosimilar BYOOVIZ. Investigators reported that IHEEZO was associated with tended-to-be less pain and fewer ocular symptoms after intravitreal injections; a retrospective analysis showed no increased risk of endophthalmitis. Harrow is continuing to recruit for the randomized QUELL study (≈236 patients), with initial results expected in Q4 2026. The share price has recently risen; the company has a market capitalization of $1.74 billion, 26% revenue growth, and analysts’ estimates indicate expected profitability in 2026. » Więcej na de.investing.com

Samsung Bioepis is restarting the US reintroduction of the ophthalmology biosimilar BYOOVIZ (ranibizumab-nuna) in partnership with Harrow, which will handle US commercial distribution. Distribution rights had been returned from Biogen to Samsung Bioepis at the end of 2025; Samsung Bioepis will remain responsible for development, approval and manufacturing. BYOOVIZ has been approved in the US since 2021 and received FDA interchangeable designation in 2023. » Więcej na de.investing.com

Harrow has announced the US launch of BYOOVIZ (ranibizumab-nuna), an interchangeable biosimilar to LUCENTIS. Marketing rights were exclusively obtained through an agreement with Samsung Bioepis; Harrow also holds rights to OPUVIZ. BYOOVIZ is approved for multiple retinal diseases and complements Harrow’s existing retina portfolio. The company points to revenue growth and analysts’ expectations for a return to profitability; common adverse events include conjunctival hemorrhage, eye pain, vitreous opacities, and increased intraocular pressure. » Więcej na de.investing.com